JP7153661B2 - 薬理学的に活性なアリール置換ピラゾロ［１，５－ａ］ピリミジン誘導体 - Google Patents

薬理学的に活性なアリール置換ピラゾロ［１，５－ａ］ピリミジン誘導体 Download PDF

Info

Publication number
JP7153661B2
JP7153661B2 JP2019549365A JP2019549365A JP7153661B2 JP 7153661 B2 JP7153661 B2 JP 7153661B2 JP 2019549365 A JP2019549365 A JP 2019549365A JP 2019549365 A JP2019549365 A JP 2019549365A JP 7153661 B2 JP7153661 B2 JP 7153661B2
Authority
JP
Japan
Prior art keywords
formula
methyl
pyrazolo
propan
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019549365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514341A (ja
JP2020514341A5 (enExample
Inventor
ボルザ、イシュトバーン
ロマーン、ヴィクトル
エーレシュ、ヤーノシュ
ハダディ、ジュジャ
フサール、ヨージェフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of JP2020514341A publication Critical patent/JP2020514341A/ja
Publication of JP2020514341A5 publication Critical patent/JP2020514341A5/ja
Application granted granted Critical
Publication of JP7153661B2 publication Critical patent/JP7153661B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019549365A 2017-03-13 2018-03-12 薬理学的に活性なアリール置換ピラゾロ［１，５－ａ］ピリミジン誘導体 Active JP7153661B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU1700107A HU231057B1 (hu) 2017-03-13 2017-03-13 Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
HUP1700107 2017-03-13
PCT/IB2018/051598 WO2018167629A1 (en) 2017-03-13 2018-03-12 PHARMACOLOGICALLY ACTIVE ARYL-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES

Publications (3)

Publication Number Publication Date
JP2020514341A JP2020514341A (ja) 2020-05-21
JP2020514341A5 JP2020514341A5 (enExample) 2021-02-12
JP7153661B2 true JP7153661B2 (ja) 2022-10-14

Family

ID=89992388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019549365A Active JP7153661B2 (ja) 2017-03-13 2018-03-12 薬理学的に活性なアリール置換ピラゾロ［１，５－ａ］ピリミジン誘導体

Country Status (6)

Country Link
US (1) US10960007B2 (enExample)
EP (1) EP3596079B1 (enExample)
JP (1) JP7153661B2 (enExample)
AR (1) AR111272A1 (enExample)
HU (2) HU231057B1 (enExample)
WO (1) WO2018167629A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
PH12022552340A1 (en) 2020-03-26 2023-11-29 Richter Gedeon Nyrt APHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA a5 RECEPTOR MODULATORS
CN111514149B (zh) * 2020-06-16 2021-02-23 中国人民解放军空军军医大学 Xav939在制备治疗孤独症谱系障碍的药物中的应用
WO2022029666A1 (en) 2020-08-05 2022-02-10 Richter Gedeon Nyrt. PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160304527A1 (en) 2015-04-20 2016-10-20 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461163B2 (en) * 2008-03-31 2013-06-11 Takeda Pharmaceutical Company Limited Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160304527A1 (en) 2015-04-20 2016-10-20 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ELISABETTA PERDONA，IN VITRO AND IN VIVO CHARACTERIZATION OF THE NOVEL GABAB RECEPTOR POSITIVE ALLOSTERIC 以下備考，NEUROPHARMACOLOGY，英国，2011年06月26日，VOL:61, NR:5，PAGE(S):957 - 966，http://dx.doi.org/10.1016/j.neuropharm.2011.06.024，MODULATOR, 2-{1-[2-(4- CHLOROPHENYL)-5-METHYLPYRAZOLO[1,5-A] PYRIMIDIN-7-YL]-2-以下省略

Also Published As

Publication number Publication date
WO2018167629A1 (en) 2018-09-20
HU231057B1 (hu) 2020-04-28
JP2020514341A (ja) 2020-05-21
HUE056561T2 (hu) 2022-02-28
AR111272A1 (es) 2019-06-26
US10960007B2 (en) 2021-03-30
EP3596079B1 (en) 2021-09-01
HUP1700107A2 (en) 2018-09-28
US20200061068A1 (en) 2020-02-27
EP3596079A1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
JP7153662B2 (ja) 薬理学的に活性な脂環式置換ピラゾロ［１，５－ａ］ピリミジン誘導体
JP7153661B2 (ja) 薬理学的に活性なアリール置換ピラゾロ［１，５－ａ］ピリミジン誘導体
JP6412148B2 (ja) 自己免疫疾患治療のためのピラゾール
JP7095106B2 (ja) オキサジアゾール一過性受容器電位チャネル阻害剤
KR20110106450A (ko) 바이시클릭 피라졸로-헤테로사이클
US12473293B2 (en) Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives
CN121127471A (zh) 作为nlrp3抑制剂的吡唑并嘧啶衍生物
JP6831376B2 (ja) トリアゾール誘導体
JP2019509987A (ja) Ｅａａｔ３阻害剤としてのピラゾール−ピリジン誘導体
JP2018531253A6 (ja) トリアゾール誘導体
EA049144B1 (ru) ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ ЗАМЕЩЕННЫЕ ПО ГЕТЕРОЦИКЛИЧЕСКОМУ ФРАГМЕНТУ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА
OA19480A (en) Pharmacologically active alicyclicsubstituted pyrazolo [1,5-a] pyrimidine derivatives.
KR19990071056A (ko) Nmda 수용체 길항제로 작용하는 4-치환-퀴놀린-2-카복실산유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220913

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221003

R150 Certificate of patent or registration of utility model

Ref document number: 7153661

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250